Resistance training helps GLP-1 users preserve strength despite muscle loss
A study found that Zepbound users who do regular strength training can still gain strength even as they lose muscle mass.
SOURCE: MarketWatch ↗
What This Means
Users of GLP-1 medications experience unintended muscle wasting alongside weight loss, a known side effect of rapid fat reduction and reduced caloric intake. Resistance training and adequate protein consumption help preserve lean mass. Muscle loss raises injury risk and reduces quality of life, which affects drug adoption and insurer costs.
Sources (1)
Every claim below links directly to the original reporting it was drawn from. Penblock synthesizes and cross-references these sources — it doesn't originate the reporting.
- MarketWatchNov 21, 2026Read the original report at MarketWatch ↗
How This Could Play Out
First assessed Nov 21
Resolved
POSSIBLEGLP-1 drug adoption accelerates as muscle-loss liability diminishes, lifting pharma sector valuations and reducing insurer resistance to coverage.
Status quo
LIKELYMuscle wasting remains a friction point in GLP-1 uptake; pharma companies continue to market drugs without addressing the side effect, leaving adoption rates constrained by patient concern.
Worsens
UNLIKELYLong-term injury claims from GLP-1-induced muscle loss mount, triggering litigation and insurer pullback on coverage, pressuring pharma margins and stock valuations.
More on GLP-1 Drug Market
- Weight-loss drugs reach 2.6 million British adults, present in 8.5% of householdsNov 19
- Ro's revenue surges tenfold after embracing GLP-1 weight-loss drugsNov 11
- Novonesis pursues gut-health supplements for obesity medication usersNov 9
- Novo lifts annual forecast on Wegovy pill sales surgeNov 4
- Analyst lifts Eli Lilly price target on obesity drug momentumOct 29
- Eli Lilly raises full-year guidance as Zepbound, Mounjaro sales accelerateOct 29
Get the market digest by email
One email each morning: yesterday's key story and what it means for markets. Free.